SCHEMBL17403402

SCHEMBL17403402

CCC(C)(C)c1ccncc1O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33
CA14 Q9ULX7 1/20 0.33
KDM5A P29375 2/20 0.33
RIPK1 Q13546 1/20 0.33
KDM4E B2RXH2 1/20 0.32
MAPKAPK2 P49137 1/20 0.32
TRPV1 Q8NER1 1/20 0.32
ALOX5 P09917 1/20 0.32
PTGS1 P23219 1/20 0.32
PTGS2 P35354 1/20 0.32
EP300 Q09472 1/20 0.32
KAT2B Q92831 1/20 0.32
KAT8 Q9H7Z6 1/20 0.32
NR3C1 P04150 2/20 0.31
PGR P06401 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13412862 0.82 ALOX5 (0.36) CA12CA1CA2CA9CA14
SCHEMBL14868405 0.79 ALDH1A1 (0.48) CA12CA1CA2CA9CA14
SCHEMBL16477946 0.78 SIRT3 (0.36) CA12CA1CA2CA9CA14
SCHEMBL18626328 0.78 PRKCH (0.34) CA12CA1CA2CA9CA14
SCHEMBL18626326 0.77 LOXL2 (0.41) TRPV1NR3C1LATS1LATS2
SCHEMBL22140201 0.77 TP53 (0.34) CA12CA1CA2CA9CA14
SCHEMBL19489324 0.76 P2RX1 (0.36) CA12CA1CA2CA9CA14
SCHEMBL17403390 0.74 CA12 (0.41) CA12CA1CA2CA9CA14
SCHEMBL21259451 0.74 RPS6KA3 (0.33) CA12CA1CA2CA9CA14
SCHEMBL23342412 0.72 CYP11B2 (0.40) CA12CA1CA2CA9CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ABM THERAPEUTICS CORP (US) 2023-09-28 US disclosed
US-9324604-B2 Gap-fill methods ROHM AND HAAS ELECTRONIC MATERIALS LLC (US) 2016-04-26 US disclosed
US-20160005641-A1 GAP-FILL METHODS U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT 2016-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ERBB2, ERBB3, ERBB4 CNR1 2818/4885CNR2 2585/4885CA12 3776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.